Mono PharmacareShare price, financial results, shareholding and management

NSE Emerge · MONOPHARMAPharmaceuticals & BiotechnologyListed 7 Sept 2023
monopharmacareltd.com ↗Live price on NSE ↗ISIN INE0OIP01012 · Lot 2,000 shares · ₹20,000
₹10.00
-2.40% on the day
Close · 18 Nov 2026
Valuation
Market cap
₹18 cr
Stock P/E
50.5peers 15.1
Book value
₹17.9
Price to book
0.56
EV / operating profit
18.4
Market cap to sales
0.11
Returns and growth
ROCE · FY26
4.5%
ROE · FY26
1.1%
ROE, 3-year average
7.1%
Operating margin · FY26
2.4%peers 10.2%
Sales growth, 3 years
71.2%
Profit growth, 3 years
-29.5%
Safety
Debt to equity
1.79peers 0.34
Borrowings
₹56.5 cr
Interest cover
1.2×
Cash from business / op. profit
58%
Debtor days
165
Pledged
0.00%
Ownership and share
Promoter holding
56.72%
Change in promoter holding
0.00 pts
Shareholders
529
52-week high / low
₹22 / ₹8
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.

Mono Pharmacare share price chart

₹10.00-51.34% 1 year

Close on 18 Nov 2026 · -2.44% on the day · Vol 4,000

Daily prices to 18 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 18 Nov 2026

1 month
+12.4%
3 months
+22.0%
6 months
-13.0%
1 year
-51.3%
Traded a day, 20 days
₹0.01 cr
Taken for delivery
90%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25-2%-89%
3 years, a year+71%-30%
Latest half, H2 FY26+22%-55%

Mono Pharmacare revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown very fast. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150200Sales, FY23: 33 ₹ cr33Net profit, FY23: 1 ₹ cr1FY23Sales, FY24: 122 ₹ cr122Net profit, FY24: 2 ₹ cr2FY24Sales, FY25: 168 ₹ cr168Net profit, FY25: 3.1 ₹ cr3.1FY25Sales, FY26: 166 ₹ cr166Net profit, FY26: 0.4 ₹ cr0.4FY26
The latest halves, ₹ crore
SalesNet profit
0255075100Sales, H2FY23: 35 ₹ cr35Net profit, H2FY23: 1 ₹ cr1H2FY23Sales, H1FY24: 67 ₹ cr67Net profit, H1FY24: 2 ₹ cr2H1FY24Sales, H2FY24: 56 ₹ cr56Net profit, H2FY24: 1 ₹ cr1H2FY24Sales, H1FY25: 87 ₹ cr87Net profit, H1FY25: 2 ₹ cr2H1FY25Sales, H2FY25: 81.2 ₹ cr81.2Net profit, H2FY25: 0.7 ₹ cr0.7H2FY25Sales, H1FY26: 66.3 ₹ cr66.3Net profit, H1FY26: 0 ₹ cr0H1FY26Sales, H2FY26: 99.4 ₹ cr99.4Net profit, H2FY26: 0.3 ₹ cr0.3H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.

Mono Pharmacare half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H2FY23H1FY24H2FY24H1FY25H2FY25H1FY26H2FY26
Sales3567568781.1866.2999.40
Expenses3363538278.2864.5297.18
Operating profit24252.901.772.22
OPM6.0%6.0%4.4%5.0%3.6%2.7%2.2%
Interest12222.461.611.71
Depreciation00000.060.060.06
Profit before tax12131.310.120.46
Net profit12120.730.020.33

Mono Pharmacare profit and loss

Full years to March, FY23 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY23FY24FY25FY26
Sales33122168.34165.69
Expenses31116160.71161.70
Operating profit267.643.99
OPM7.0%5.0%4.5%2.4%
Other income000.980.01
Interest134.033.32
Depreciation000.130.11
Profit before tax134.460.58
Tax rate0.0%33.3%30.7%39.7%
Net profit123.090.35
EPS ₹0.761.381.750.20
Dividend payout0.0%0.0%0.0%0.0%

The years to FY24 come rounded to the nearest crore in the source.

Earnings per share before FY26 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.

Mono Pharmacare profitability

Margins and returns on capital

Last year the company kept less from each rupee of sales than the year before. It earns a low return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%2%4%6%8%FY23: 7.0%7.0%FY23FY24: 5.0%5.0%FY24FY25: 4.5%4.5%FY25FY26: 2.4%2.4%FY26
Per cent
FY23FY24FY25FY26
Operating margin7.0%5.0%4.5%2.4%
Tax rate0.0%33.3%30.7%39.7%
ROCE·9.8%11.0%4.5%
ROE·9.8%10.4%1.1%
Dividend payout0.0%0.0%0.0%0.0%

Mono Pharmacare debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown. Its loans are now larger than its own money. Last year the business brought in more cash than it showed as profit. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
0204060Net worth, FY23: 13 ₹ cr13Borrowings, FY23: 40 ₹ cr40FY23Net worth, FY24: 28 ₹ cr28Borrowings, FY24: 41 ₹ cr41FY24Net worth, FY25: 31.2 ₹ cr31.2Borrowings, FY25: 53.6 ₹ cr53.6FY25Net worth, FY26: 31.6 ₹ cr31.6Borrowings, FY26: 56.5 ₹ cr56.5FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-40-20020Cash from the business, FY23: -40 ₹ cr-40Net profit, FY23: 1 ₹ cr1FY23Cash from the business, FY24: -9 ₹ cr-9Net profit, FY24: 2 ₹ cr2FY24Cash from the business, FY25: -4.3 ₹ cr-4.3Net profit, FY25: 3.1 ₹ cr3.1FY25Cash from the business, FY26: 2.3 ₹ cr2.3Net profit, FY26: 0.4 ₹ cr0.4FY26

Bars below the line are cash going out.

Mono Pharmacare balance sheet

At each 31 March · ₹ crore

₹ crore
FY23FY24FY25FY26
Equity capital121817.6717.67
Reserves11013.5313.88
Net worth132831.2031.55
Borrowings404153.5656.50
Other liabilities101225.2934.24
Total liabilities6381110.05122.29
Fixed assets110.990.88
Capital work in progress0000
Investments1000
Other assets6180109.06121.41
Receivables··41.8974.94
Inventory··55.3942.43
Cash··0.700.98
Trade payables··18.8029.22

Mono Pharmacare cash flow

₹ crore

₹ crore
FY23FY24FY25FY26
Cash from operations-40-9-4.302.30
Cash from investing-10-0.230
Cash from financing4184.86-2.01
Net cash flow0-10.330.29
Capital spending··0.230

Working capital

Days

Days
FY23FY24FY25FY26
Debtor days2419491165
Inventory days40813913399
Days payable87324568
Cash conversion cycle563202179196
Working capital days299131120126

Mono Pharmacare peers and competitors

Listed SME companies in the same industry

By sales, Mono Pharmacare is number 6 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Sat Kartar Life22012.92011712.0%0.03
Infinium Pharmachem47138.719012.211.4%0.19
Zenith Drugs6817.21713.97.1%0.75
Mono Pharmacare1850.51660.42.4%1.79
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
Median of the 10 others18715.11399.310.2%0.34

Mono Pharmacare shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.

Promoters
56.72%
0.00 pts since Sep 23
Foreign investors (FIIs)
0.00%
at Mar 25; not in the latest pattern
Indian institutions (DIIs)
0.00%
at Mar 25; not in the latest pattern
HNIs (over ₹2 lakh each)
22.42%
-1.22 pts since Sep 23
Small holders (up to ₹2 lakh)
10.86%
-3.63 pts since Sep 23
Companies and others
10.00%
+4.85 pts since Sep 23
Number of shareholders
529
621 in Sep 23

Mono Pharmacare shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Sep 23Dec 23Mar 24Sep 24Mar 25Sep 25Mar 26
Promoters56.72%56.72%56.72%56.72%56.72%56.72%56.72%
Foreign investors (FIIs)0.00%0.00%0.00%0.00%0.00%--
Indian institutions (DIIs)0.00%0.00%0.00%0.00%0.00%--
HNIs (over ₹2 lakh each)23.64%24.43%26.54%25.09%25.22%23.71%22.42%
Small holders (up to ₹2 lakh)14.49%12.77%10.15%10.18%10.37%10.76%10.86%
Companies and others5.15%6.08%6.59%8.01%7.69%8.81%10.00%
Number of shareholders621528418463478514529

The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.

Mono Pharmacare latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹99.4 cr (+22%), net profit ₹0.3 cr (-55%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters unchanged at 56.72%.

Mono Pharmacare annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Offer document

Mono Pharmacare share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Mono Pharmacare's data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,76,68,564 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • ✓Earnings per share moves in line with profit across the years shown.
  • ✓Revenue and profit are reported for every year shown, FY23 to FY26.
  • iPrices run to the close on 9 Oct 2026, from the exchange's daily figures.

Questions people ask about Mono Pharmacare

What does Mono Pharmacare do?

Mono Pharmacare is an SME company listed on NSE Emerge, in pharmaceuticals & biotechnology.

What is the share price of Mono Pharmacare?

₹10 at the close on 18 Nov 2026, from the exchange's daily figures.

What is the market cap of Mono Pharmacare?

₹18 cr at the close on 18 Nov 2026, on 1,76,68,564 shares.

What is the P/E of Mono Pharmacare?

50.5 times FY26 profit at the close on 18 Nov 2026 (our arithmetic).

What are Mono Pharmacare's revenue and profit?

Revenue ₹166 cr and profit after tax ₹0 cr in FY26.

Who are the promoters of Mono Pharmacare?

The promoter group; promoters held 56.72% at 31 March 2026.

What is Mono Pharmacare's website?

monopharmacareltd.com

More SME companies like Mono Pharmacare

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2023 →

Built from 33 exchange announcements, 7 shareholding patterns and 4 years of reported results. Every figure carries its source; where the documents are silent, the page says so.